Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/16/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 4/16/21 | Free | Chief Financial Officer | 569,947 | 1.2238% | ||
| 4/16/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| -2.01% | -7.86% | +54.60% | +70.97% | 70.44B | |
| +3.84% | -10.61% | +6.97% | +57.43% | 50.31B | |
| +3.35% | +1.60% | +10.58% | +40.01% | 47.51B | |
| +0.51% | +1.51% | +27.96% | +31.68% | 42.91B | |
| +2.70% | -3.66% | +307.41% | +467.17% | 40.39B | |
| +0.69% | -3.44% | +9.52% | +102.07% | 39.69B | |
| +0.06% | -1.43% | +10.47% | +43.27% | 30.59B | |
| -2.95% | -14.09% | +37.94% | +1.30% | 26.8B | |
| -0.39% | -6.92% | -13.60% | -8.57% | 22.36B | |
| Average | +0.74% | -5.58% | +50.20% | +89.48% | 41.22B | |
| Weighted average by Cap. | +0.94% | -5.44% | +53.17% | +94.97% |
Employees
51
